AAV Gene Therapy Process
Development & CMC Consulting
Phase-appropriate viral vector manufacturing development that accelerates your AAV gene
therapy program, from construct design through commercial scale-up and BLA filing.
Efficient & Results-Driven Driving Success Across the Drug Development Lifecycle
Your product is your manufacturing and testing process. By building robust processes and analytics early in the drug product lifecycle, DES Pharma ensures you get your AAV gene therapy, and all biologics, to patients safely and efficiently.
Using our extensive experience in AAV gene therapy manufacturing, viral vector process development, and CMC regulatory strategy, we eliminate wasted effort and experimentation, delivering fast, reliable, and compliant drug supply to meet your clinical and corporate milestones.
AAV Gene Therapy Manufacturing Services
Specialized capabilities for adeno-associated virus development across all platforms and serotypesIncluding AAV capsid development, producer cell line optimization, and viral vector manufacturing scale-up. Our consultants have hands-on experience with AAV2, AAV5, AAV8, AAV9, and novel capsid variants across triple plasmid transfection, baculovirus insect cell, and HSV helper virus platforms.
A Phase-Appropriate CMC Approach
Cutting Out Excess &
Risks at Every Stage
Fast-tracking drug development and optimizing patient safety, production efficiency, and supply reliability to accelerate market access for AAV gene therapies and biologics.
Begin with the Commercial End State in Mind
- Construct Design / Plasmid Manufacturing
- AAV Platform Selection (triple plasmid vs. baculovirus)
- Toxicology Lot Production & Release
- Process Mapping / Supply Planning
- Empty/Full Capsid Ratio Optimization Strategy
- Producer or Transient Cell Line Development
- Manufacturing Process Development & Product Characterization
- Statistical Process Development & Design of Experiments
- IND Authorship and CMC Module 3.2 Support
- Serum-Free Suspension Adaptation Planning
Lay the Groundwork for Reliable Clinical Supply
- Detailed Process Description & Sampling Plan
- Tech Transfer of AAV Manufacturing Process
- Person-In-Plant Support During Tech Transfer
- Stability Study Design (ICH Q5C)
- GMP Cell Banking (MCB / WCB)
- Process Optimization & Operational Excellence
- RFP / CDMO Vendor Selection Support
- Facility Fit Assessment & Scale-Up Strategy
- Clinical Batch Release & Review
- Raw Material Risk & Gap Assessment
- Type B / C FDA Meeting Support & Briefing Documents
- Comparability Protocol & Report
Ensure Process Control & Submission Readiness
- Process Characterization Study Design
- Historical Process Performance Analytics
- Process Validation Master Plan & Protocols (PPQ)
- Viral Clearance Study Support (AAV-specific)
- Resin Lifetime Study Support
- Pre-Approval Inspection (PAI) Readiness
- Adventitious Agent Testing Strategy
- Scale-Down Model Qualification
- FMEA Drafting & Process Control Strategy
- Commercial Master Batch Record / Sample Plan
- Bio-Burden / Contamination Control Strategy
- Leachable / Extractable & Impurity Clearance
- BLA Submission Filing Support
- Container Closure & Packaging Validation
Maintain Compliance & Expand Your Market
- Continuous Process Validation Protocol & Data Analysis
- Commercial Batch Disposition & Release Support
- Market Expansion Filing Support
- Competitive Intelligence & Due Diligence
- Commercial Site / Tech Transfer & Comparability
- Post-Approval Inspection Mitigation
- Vector Shedding Protocol Maintenance
AAV Manufacturing Expertise Specialized Viral Vector Process Development
At DES Pharma, we bring deep expertise in AAV gene therapy manufacturing across all serotypes and production platforms. Our consultants have hands-on experience with AAV2, AAV5, AAV8, AAV9, and novel capsid variants, supporting programs through every critical development milestone from construct design through commercial manufacturing.
We understand the unique challenges of viral vector process development: optimizing empty/full capsid ratios, scaling from adherent to suspension cell culture, selecting appropriate downstream purification strategies, and navigating complex regulatory expectations for gene therapy CMC.
Whether transitioning from triple plasmid transfection to a baculovirus insect cell system, preparing your first IND submission, or executing PPQ batches ahead of a BLA, our team delivers the technical depth and regulatory insight to accelerate your program and meet FDA and EMA expectations.
Triple Plasmid → Baculovirus Platform Transitions
Comparative platform assessment, technology transfer packages, and manufacturing robustness evaluation for HEK293 and Sf9 cell-based systems
Upstream Bioreactor Scale-Up
Adherent to suspension adaptation, bioreactor optimization (wave, stirred-tank), MOI and infection timing studies, and cell viability management
Downstream Purification Strategy
Ultracentrifugation, iodixanol gradient, affinity chromatography (AAVX, AVB Sepharose), and ion-exchange polishing (platform and custom approaches)
Empty/Full Capsid Control & Optimization
Analytical ultracentrifugation (AUC), AEX chromatography strategies, and process modification to achieve target full capsid percentage specifications
IND CMC Module 3.2 Authorship
Gene therapy-specific manufacturing section drafting, process description, critical quality attributes, and FDA/EMA-aligned regulatory strategy
Rational Design, Reliable Results
Emphasizing Process
Design & Product Quality
Our core principles drive measurable outcomes for AAV gene therapy
and biologics programs at every stage.
High Product Quality
Built on rational, data-driven process design that establishes critical quality attributes (CQAs) and process parameters from day one.
Timeline Acceleration
We perform only the core experiments necessary to achieve meaningful results, eliminating non-essential studies that delay IND and BLA timelines.
Supply Reliability
Our process helps ensure robust supply and predictable manufacturing performance, critical for gene therapy programs with complex logistics requirements.
Proven Technologies
We leverage established manufacturing platforms and validated analytical methods to minimize technical risk and regulatory uncertainty.
Regulatory Alignment
Deep knowledge of FDA and EMA gene therapy CMC expectations, ICH Q8/Q9/Q10/Q11, and current CBER guidance for viral vectors.
CDMO Partnership Support
End-to-end CDMO selection, RFP management, technical due diligence, and tech transfer oversight for AAV and biologics manufacturing.
Supply Planning & Commercial Readiness Strategic Planning for Reliable Supply
With experience in commercial processes, DES Pharma guides program development toward outcomes that meet both patient and corporate needs efficiently, including the unique supply chain requirements of viral vector gene therapy products.
Supply Modeling Driving Scalable Success
Demand planning, capacity allocation, and yield modeling to ensure you never face clinical material shortfalls.
Vendor Selection & Facility Design
Comprehensive CDMO assessment including facility capabilities, GMP compliance status, and capacity commitments for AAV manufacturing.
Sufficient Clinical & Commercial Material
Scale-up strategy ensuring manufacturing capacity meets clinical enrollment projections and eventual commercial demand.
Get Started Advance Your AAV Gene Therapy Program with Confidence
Start building a reliable, regulatory-ready viral vector manufacturing process today.